Study of MBRC-201 for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin clinical trials.
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a solid tumor that has spread or cannot be removed, and standard treatments no longer work or are not an option.
- You need to be in fairly good health, able to do daily activities with little help (ECOG score 0-2).
- Your liver, kidney, and blood cell counts must be within certain limits (you'll have tests to check).
- You must agree to use effective birth control during the study and for 6 months after your last dose of the study drug.
- You must have a tumor sample available (from a prior biopsy or surgery) if possible.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, MBRC-101, that targets a protein called EphA5 found on some cancer cells. It is for people with advanced solid tumors (like lung, breast, or pancreatic cancer) that have stopped responding to other treatments. The study aims to find a safe dose and see if the drug can shrink tumors.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
This trial tests a new drug called CMAB017 for people with advanced solid tumors who have run out of standard options. The goal is to find a safe dose and see how well it is tolerated.
This trial is testing a new drug called DM5167 for people whose advanced solid tumors have a BRCA1 or BRCA2 gene mutation. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests MPB-1734, a new study drug, in adults with advanced solid tumors that can’t be removed and for which standard treatment has stopped working. It aims to find out how safe it is and whether it can shrink or control the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.